Swedish firm achieves delicate balance in €336m pharma deal

Swedish investment firm Investor has agreed a rare deal in which it held a substantial stake in both the buyer and the seller.

A portfolio company of Investor, Biovitrum, acquired Swedish Orphan International, in which Investor is also the joint-largest shareholder, holding SEK3.5bn (€336m). Owing to a potential conflict of interest, Investor took no part in the buyer's decision-making process to bid, a spokesman said.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump